Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-PET/CT in Cancer of Unknown Primary
NCT05263700Unknown
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga FAPI-46 in cancer of unknown primary (CUP), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Proportion of patients in which a likely tissue of origin is identified using 68Ga-FAPI-PET/CT at 12 months. Status: unknown.
02
Drugs
68Ga FAPI-46
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT05263700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263700.